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Abstract
The interaction of two ruthenium(Ill) complexes exhibiting high anticancer activity namely trans-
Indazolium(bisindazole) tetrachloromthenate(lll), Hlnd[Rulnd2CI4], and trans-lmidazolium (bis-
imidazole) tetrachlommthenate(lll), HIm[Rulm2CI4],- with human serum apotransferrin has been
investigated through spectroscopic and chromatographic techniques with the ultimate goal of
preparing adducts with good selectivity for cancer cells due to the fact that tumour cells express
high amounts of transferrin receptors on their cell surface.
Whereas the binding of HIm[Rulm2CI4] to human serum apotransferdn takes several hours,
Hlnd[Rulnd2CI4], the less toxic complex, gives rise to a well defined 2:1 complex within a few
minutes. Hlnd[Rulnd2CI4] will react with apotransferrin only in the presence of bicarbonate, this
anion dictating the kinetic and mechanistic characteristics of protein-binding.
Circular dichroism studies had previously indicated that binding of both Ru(lll) complexes occurs
around the unoccupied iron(Ill) binding sites; this result is now confirmed by preliminary X-ray
data of Hlnd[Rulnd2CI4] and HIm[Rulm2CI4] bound to apolactoferdn, a related iron protein. The
crystallograhic data reveals that binding of both complexes takes place at histidine residues, and
that the ligand (indazole) remains bound in the case of Hlnd[Rulnd2CI4].
Introduction
The Ru(lll) complexes, HIm[Rulm2CI4]- abbrev, m-im (Fig. 1A) and Hlnd[Rulnd2CI4] abbrev.
ru-ind (Fig. 1B), show a high antitumour activity in the autocthonous colorectal carcinoma model
of rats, a model which simulates the colon cancer of humans very well [1].
H
Figure 1. Scheme of the two ruthenium(Ill) complexes: A) ru-im; B) ru-ind.
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Recently, it has been shown by Kratz et al. that the most promising complex, ru-ind, which is far
less toxic in long term application than the imidazole analogue, binds within a few minutes to the
serum proteins albumin and transferrin [2]. Furthermore, it has been demonstrated that the
apotransferdn-bound complex exhibits a higher antitumour activity against human colon cancer
cells when compared to the albumin-bound or "free" species [3]. This result suggests that
apotransferrin can act as a natural carder of the drug to the tumor tissues owing to the high
affinity between this metal transport protein and the large number of transferrin receptors on the
surface of tumor cells [4]. Indeed, it has been previously reported that transferdn is responsible for
the selective delivery of radioactive 67Ga(lll) complexes to tumor tissues [5], and it is therefore
tempting to exploit the transferrin cycle as a "natural" mute for selective delivery of cytostatic
drugs to cancer cells. We therefore decided to investigate the kinetic and mechanistic
characteristics of the reaction between the two ruthenium(Ill) complexes and apotransferdn with
the aid of HPLC. Furthermore, in order to obtain more precise information on the binding sites of
the complexes, soaking experiments of apolactoferrin crystals with the two Ru(lll) complexes
were carried out and preliminary results of the subsequent X-ray structure analyses are reported
in this paper.
Materials and Methods
The ruthenium(Ill) complexes were synthesized as described earlier [1] and were used in all the experiments
from a freshly prepared 5x10"4 M aqueous solution for ru-ind and a lx10"2 M aqueous solution for ru-im.
Human serum apotransferrin (98%, crystalline, essentially iron free, MW 80,000) (apoTf hereafter) were
purchased from Sigma Chemical Company and the latter purified according to standard procedures [6]. For
the kinetic and mechanistic studies a physiological buffer was used so that the final concentrations were
0.004 M NaH2PO4, 0.1 M NaCI and 0.025 M NaHCO3 with pH=7.4.
HPLC studies were performed with a Perkin Elmer Series 410 LC pump and a LC-95 UV/visible
spectrophotometer detector. The column used was: (a) Bio-Sil SEC 250, (300 mm x 7.8 mm) from Bio-
RAD, mobile phase: 0.15 M NaCI, 0.01 M NaH2PO4, 5% CH3CN pH 7.0.
Human apolactoferrin was prepared and crystallized (in deglycosylated form) as described by Norris et al.
[7]. The crystals of apolactoferrin were reacted with the Ru(lll) complexes by soaking them in mother liquor
(0.05 M tris-buffer, pH 7.8, containing 7% ethanol and 5% 2-methyl-2,4-pentanediol) to which NaHCO3
(0.01M) and ru-im or ru-ind had been added to concentrations of 0.01 M and 0.0005 M respectively.
Soaking times between 12 hours and 4 weeks were used after which the crystals were removed and
mounted in glass capillaries. X-ray data were collected with a Rigaku R-axis image plate detector on a
rotating anode generator to a resolution of 2.2 A.
Results and Discussion
Kinetics and mechanism ofprotein-binding
The reactivity pattern of both ru-ind and ru-im with apotransferrin is complicated by the occurence
of concomitant hydrolysis processes and substitution reactions with solute species. Surprisingly, in
spite of their structural similarity, ru-im and ru-ind exhibit very different reactivity patterns which
are reflected in the respective protein-binding abilities.
The major differences between the behavior of the two complexes is a kinetic and mechanistic
one. Binding of ru-ind to apotransferdn proceeds through the formation of two intermediates which
then bind rapidly to the protein as can be seen in the respective chmmatograms (Fig.2 A-C).
Fig. 2A shows a chromatogram of ru-ind by itself, it can be clearly seen that the complex anion
[Rulnd2CI4]- (12.5 min) is separated from the cation [Hind]+ (15.8 min). Fig. 2B shows the
chromatogram of ru-ind and apotransferrin after only 3 min of incubation. The original complex
(12.5 min) has disappeared, but two intermediate complexes appear (peaks at 10.3 and 11
minutes), and them is already binding to apotransferrin (5.5 min). After 5 minutes (Fig 2C) the
reaction is complete, all of the complex now being bound to apotransferrin. The important thing to
note is that this reaction takes place only in the presence of bicarbonate. This is a novel feature of
this ruthenium(Ill) complex and implies that it is not simple hydrolysis but that a number of
substitution reactions involving bicarbonate are taking place before binding to apotransferrin.
In contrast, it takes 5 hours at 37 oc for ru-im to bind to apotransferrin; the reaction does not
depend on bicarbonate, and no intermediates are observed in the chromatograms (Fig. 3A,B).
Fig. 3A shows the reaction of ru-im and apotransferrin after 3 minutes followed at 254 nm and 345
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Figure 2A-C Chromatograms of: A) ru-ind, B) ru-ind plus apoTf after 3 minutes, C) ru-ind plus apoTf after
5 minutes. All chromatograms were performed on a size exclusion column and recorded at 280 and 360
nm. ru-ind was incubated with apoTf in the physiological buffer at T = 37 C at a ratio of 1"1, the
concentration of apoTf being lx10 M. The peak of apoTf is labelled T.
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Figure 3A, B: Chromatograms of: A) ru-im plus apoTf after 3 minutes, B) ru-im plus apoTf after 2 hours. The
chromatograms were performed on a size exclusion column and recorded at 254 and 340 nm. ru-im was
incubated with apoTf in the physiological buffer at T = 37 C at a ratio of 1"1, the concentration of apoTf
being 5x10"4M. The peak of apoTf is labelled A.
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nm (LMCT): only one peak is seen for ru-im at 10 min suggesting that the complex exists in
solution as a stable ionic pair. Another thing which can be observed is that after this short time
interval them is neither binding to apotransferrin nor detection of intermediates. Fig. 3B shows the
chromatogramm of ru-im and apotransferrin after 2 hours incubation. The original complex is still
present although the signal intensity is reduced to about one half of the original value, and a clear
signal at 5.5 min, the position of apotransferrin, is now observed at 340 nm. A further thing to note
is that no signal for a free imidazolium ion appears in the chromatogramm indicating that the
original imidazolium (bisimidazole)tetrachlororuthenate complex might bind to apotransferdn as a
trts-imidazole complex. Protein-binding is complete after approximately 5 hours when the
chromatogram shows only the apotransferrin peak at both wavelengths.
Specificity ofprotein-binding and crystallographic studies
We have previously shown by circular dichroism (CD) spectroscopy that 2 equivalents of ru-ind
can be specifically bound by apotransferdn indicating that binding takes place around the two
iron(Ill) binding sites of the protein (2).
In order to gain more definitive information on the binding sites for the two Ru(lll) complexes,
crystallographic experiments were carded out. Apolactoferdn was chosen rather than
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apotransferrin because of the availability of suitable crystals, but the binding behaviour should be
similar given the strong structural similarities between lactoferdns and transferrins (8). The
analyses carded out to date include one in which a crystal of apolactoferdn was soaked in ru-ind
for a period of 12 hours, and a second in which ru-im was used for a much longer period of 4
weeks. Although the results are preliminary only, as full crystallographic refinements have not yet
been carded out, difference Fourier maps show very clearly that the preferred binding sites for the
Ru(lll) complexes are at histidine residues of the protein, presumably following the loss of one or
more of the chloride ligands. In the case of ru-ind, with a short soaking time and a low
concentration, binding occurs specifically at His 253 in the open binding cleft of the N-terminal
half of the protein; this residue is one of the iron ligands in the diferric form of lactoferrin or
transferrin (8). The two indazole ligands remain coordinated to the ruthenium atom (Fig. 4a).
Figure 4a: Difference ’elecfion
density for ru-ind in the N-
terminal site of human apo-
lactoferrin, showing that the
two indazole ligands are
retained. The Ru atom binds
to His 253, and the nearby
side chain of Lys 301 may
help stabilize binding.
Figure 4b: Ribbon diagram
showing sites of ru-im binding
after soaking for 4 weeks.
Sites are: (1) His 253, (2) His
597, (3) His 590, (4) His 654.
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When ru-im is used, with the higher concentration and longer soaking time, more sites are
occupied (Fig. 4b). These include the histidine ligands at both iron binding sites, His 253 and His
597, as well as other non-specific sites where histidines are exposed on the protein surface, i.e.
His 590 and His 654. In these cases the preliminary nature of the results is such that we cannot
yet say to what extent the imidazole ligands remain bound.
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